These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17894827)

  • 1. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
    Hitman GA; Colhoun H; Newman C; Szarek M; Betteridge DJ; Durrington PN; Fuller J; Livingstone S; Neil HA;
    Diabet Med; 2007 Dec; 24(12):1313-21. PubMed ID: 17894827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
    Thomason MJ; Colhoun HM; Livingstone SJ; Mackness MI; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
    Diabet Med; 2004 Aug; 21(8):901-5. PubMed ID: 15270795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.
    Holman RR; Paul S; Farmer A; Tucker L; Stratton IM; Neil HA;
    Diabetologia; 2009 Jan; 52(1):50-9. PubMed ID: 19002433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
    Colhoun HM; Thomason MJ; Mackness MI; Maton SM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
    Diabet Med; 2002 Mar; 19(3):201-11. PubMed ID: 11918622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group
    Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The collaborative atorvastatin diabetes study: preliminary results.
    Owen OG
    Int J Clin Pract; 2005 Jan; 59(1):121-3. PubMed ID: 15707477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
    Gumprecht J; Gosho M; Budinski D; Hounslow N
    Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
    Charlton-Menys V; Betteridge DJ; Colhoun H; Fuller J; France M; Hitman GA; Livingstone SJ; Neil HA; Newman CB; Szarek M; DeMicco DA; Durrington PN
    Diabetologia; 2009 Feb; 52(2):218-25. PubMed ID: 18972097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia.
    Tanaka A; Yamada N; Saito Y; Kawakami M; Ohashi Y; Akanuma Y
    Clin Chim Acta; 2001 Oct; 312(1-2):41-7. PubMed ID: 11580908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
    Arca M
    Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin].
    Griebenow R
    Internist (Berl); 2005 Mar; 46(3):350-2. PubMed ID: 15696286
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Lancet; 2003 Apr; 361(9364):1149-58. PubMed ID: 12686036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.
    Hsue PY; Bittner VA; Betteridge J; Fayyad R; Laskey R; Wenger NK; Waters DD
    Am J Cardiol; 2015 Feb; 115(4):447-53. PubMed ID: 25637322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
    Liu PY; Lin LY; Lin HJ; Hsia CH; Hung YR; Yeh HI; Wu TC; Chen JY; Chien KL; Chen JW
    PLoS One; 2013; 8(10):e76298. PubMed ID: 24098467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of atorvastatin on pancreatic Beta-cell function and insulin resistance in type 2 diabetes mellitus patients: a randomized pilot study.
    Goyal A; Singh S; Tandon N; Gupta N; Gupta YK
    Can J Diabetes; 2014 Dec; 38(6):466-72. PubMed ID: 24933106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.
    Annemans L; Marbaix S; Webb K; Van Gaal L; Scheen A
    Clin Drug Investig; 2010; 30(2):133-42. PubMed ID: 20067331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
    Betteridge DJ; Gibson JM
    Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience.
    Velussi M; Cernigoi AM; Tortul C; Merni M
    Diabetes Nutr Metab; 1999 Dec; 12(6):407-12. PubMed ID: 10782562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.